Valvular Heart Disease

  • Sammy Elmariah
  • James L. JanuzziJr.
  • James L. JanuzziJr.
  • Aidan W. Flynn
  • Praveen Mehrotra
  • Igor F. Palacios
  • Igor F. Palacios


Valvular heart disease is a growing public health concern – as our population ages, the prevalence of valvular heart disease will only rise. The expansive topic encompasses numerous disease entities, complex hemodynamics, invasive and noninvasive testing, and involved management decisions. In addition, perhaps more so than any other topic in cardiology, the diagnosis and management of valvular heart disease is dependent on the history and physical examination. Such complexity makes valvular heart disease a prime topic for cardiology board examinations.


Mitral Valve Right Ventricular Aortic Stenosis Infective Endocarditis Aortic Regurgitation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Aortic regurgitation


Aortic stenosis


Aortic valve


Percutaneous balloon aortic valvuloplasty


Cross sectional area


Diastolic filling period


Deceleration time


Heart rate


Left ventricular


Left ventricular outflow tract


Mitral regurgitation


Mitral stenosis


Mitral valve area


Mitral valve gradient


Mitral valve replacement


New York Heart Association


Pressure half-time


Percutaneous mitral valvuloplasty


Pulmonic regurgitation


Pulmonic stenosis


Right atrial


Right ventricular


Tricuspid regurgitation


Tricuspid stenosis


Velocity time integral


  1.  1.
    Selzer A. Changing aspects of the natural history of valvular aortic stenosis. N Engl J Med. 1987;317:91–8.PubMedCrossRefGoogle Scholar
  2.  2.
    Mohler 3rd ER, Gannon F, Reynolds C, et al. Bone formation and inflammation in cardiac valves. Circulation. 2001;103:1522–8.PubMedCrossRefGoogle Scholar
  3.  3.
    O’Brien KD, Shavelle DM, Caulfield MT, et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation. 2002;106:2224–30.PubMedCrossRefGoogle Scholar
  4.  4.
    Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the early lesion of ‘degenerative’ valvular aortic stenosis. Histo­logical and immunohistochemical studies. Circulation. 1994;90:844–53.PubMedCrossRefGoogle Scholar
  5.  5.
    Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003;107:2181–4.PubMedCrossRefGoogle Scholar
  6.  6.
    Goldbarg SH, Elmariah S, Miller MA, et al. Insights into degenerative aortic valve disease. J Am Coll Cardiol. 2007;50:1205–13.PubMedCrossRefGoogle Scholar
  7.  7.
    Michelena HI, Desjardins VA, Avierinos JF, et al. Natural history of asymptomatic patients with normally functioning or minimally dysfunctional bicuspid aortic valve in the community. Circulation. 2008;117:2776–84.PubMedCrossRefGoogle Scholar
  8.  8.
    Roberts WC, Janning KG, Ko JM, et al. Frequency of congenitally bicuspid aortic valves in patients >/=80 years of age undergoing aortic valve replacement for aortic stenosis (with or without aortic regurgitation) and implications for transcatheter aortic valve implantation. Am J Cardiol. 2012;109:1632–6.PubMedCrossRefGoogle Scholar
  9.  9.
    Blais C, Burwash IG, Mundigler G, et al. Projected valve area at normal flow rate improves the assessment of stenosis severity in patients with low-flow, low-gradient aortic stenosis: the multicenter TOPAS (Truly or Pseudo-Severe Aortic Stenosis) study. Circulation. 2006;113:711–21.PubMedCrossRefGoogle Scholar
  10. 10.
    Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52:e1–142.PubMedCrossRefGoogle Scholar
  11. 11.
    Gorlin R, Gorlin SG. Hydraulic formula for calculation of the area of the stenotic mitral valve, other cardiac valves, and central circulatory shunts. I. Am Heart J. 1951;41:1–29.PubMedCrossRefGoogle Scholar
  12. 12.
    Hakki AH, Iskandrian AS, Bemis CE, et al. A simplified valve formula for the calculation of stenotic cardiac valve areas. Circulation. 1981;63:1050–5.PubMedCrossRefGoogle Scholar
  13. 13.
    Otto CM, Pearlman AS, Gardner CL. Hemodynamic progression of aortic stenosis in adults assessed by Doppler echocardiography. J Am Coll Cardiol. 1989;13:545–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Cheitlin MD, Gertz EW, Brundage BH, et al. Rate of progression of severity of valvular aortic stenosis in the adult. Am Heart J. 1979;98:689–700.PubMedCrossRefGoogle Scholar
  15. 15.
    Rosenhek R, Binder T, Porenta G, et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med. 2000;343:611–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Novaro GM, Katz R, Aviles RJ, et al. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. J Am Coll Cardiol. 2007;50:1992–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Ross Jr J, Braunwald E. Aortic stenosis. Circulation. 1968;38:61–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389–97.PubMedCrossRefGoogle Scholar
  19. 19.
    Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343–56.PubMedCrossRefGoogle Scholar
  20. 20.
    Chan KL, Teo K, Dumesnil JG, et al. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306–14.PubMedCrossRefGoogle Scholar
  21. 21.
    Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597–607.PubMedCrossRefGoogle Scholar
  22. 22.
    Cribier A, Savin T, Saoudi N, et al. Percutaneous transluminal valvuloplasty of acquired aortic stenosis in elderly patients: an alternative to valve replacement? Lancet. 1986;1:63–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Freeman RV, Otto CM. Aortic valve disease. In: Fuster V, Walsh R, Harrington R, editors. Hurst’s the heart. 13th ed. New York, NY: McGraw-Hill; 2010.Google Scholar
  24. 24.
    Stout KK, Verrier ED. Acute valvular regurgitation. Circulation. 2009;119:3232–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Zoghbi WA, Enriquez-Sarano M, Foster E, et al. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr. 2003;16:777–802.PubMedCrossRefGoogle Scholar
  26. 26.
    Maroo A, Deedy M, Griffin BP. Aortic valve disease. In: Griffen BP, Topol EJ, editors. Manual of cardiovascular medicine. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.Google Scholar
  27. 27.
    Sellers RD, Levy MJ, Amplatz K, et al. Left retrograde cardioangiography in acquired cardiac disease: technic, indications and interpretations in 700 cases. Am J Cardiol. 1964;14:437–47.PubMedCrossRefGoogle Scholar
  28. 28.
    Bolen JL, Alderman EL. Hemodynamic consequences of afterload reduction in patients with chronic aortic regurgitation. Circulation. 1976;53:879–83.PubMedCrossRefGoogle Scholar
  29. 29.
    Greenberg BH, DeMots H, Murphy E, et al. Beneficial effects of hydralazine on rest and exercise hemodynamics in patients with chronic severe aortic insufficiency. Circulation. 1980;62:49–55.PubMedCrossRefGoogle Scholar
  30. 30.
    Lin M, Chiang HT, Lin SL, et al. Vasodilator therapy in chronic asymptomatic aortic regurgitation: enalapril versus hydralazine therapy. J Am Coll Cardiol. 1994;24:1046–53.PubMedCrossRefGoogle Scholar
  31. 31.
    Bonow RO, Nikas D, Elefteriades JA. Valve replacement for regurgitant lesions of the aortic or mitral valve in advanced left ventricular dysfunction. Cardiol Clin. 1995;13:73–83, 5.PubMedGoogle Scholar
  32. 32.
    Otto CM, Bonow RO. Valvular heart disease. In: Libby P, Bonow RO, Mann DL, Zipes EP, editors. Braunwald’s heart disease: a textbook of cardiovascular medicine. 8th ed. St. Louis, MO: W.B. Saunders; 2007.Google Scholar
  33. 33.
    Wilkins GT, Weyman AE, Abascal VM, et al. Percutaneous balloon dilatation of the mitral valve: an analysis of e­chocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J. 1988;60:299–308.PubMedCrossRefGoogle Scholar
  34. 34.
    Abascal VM, Wilkins GT, O’Shea JP, et al. Prediction of successful outcome in 130 patients undergoing percutaneous balloon mitral valvotomy. Circulation. 1990;82:448–56.PubMedCrossRefGoogle Scholar
  35. 35.
    Palacios IF. Farewell to surgical mitral commissurotomy for many patients. Circulation. 1998;97:223–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Reyes VP, Raju BS, Wynne J, et al. Percutaneous balloon valvuloplasty compared with open surgical commissurotomy for mitral stenosis. N Engl J Med. 1994;331:961–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Palacios IF, Sanchez PL, Harrell LC, et al. Which patients benefit from percutaneous mitral balloon valvuloplasty? Prevalvuloplasty and postvalvuloplasty variables that predict long-term outcome. Circulation. 2002;105:1465–71.PubMedCrossRefGoogle Scholar
  38. 38.
    Ben Farhat M, Ayari M, Maatouk F, et al. Percutaneous balloon versus surgical closed and open mitral commissurotomy: seven-year follow-up results of a randomized trial. Circulation. 1998;97:245–50.PubMedCrossRefGoogle Scholar
  39. 39.
    Enriquez-Sarano M, Schaff HV, Orszulak TA, et al. Valve repair improves the outcome of surgery for mitral regurgitation. A multivariate analysis. Circulation. 1995;91:1022–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Gillinov AM, Cosgrove DM, Blackstone EH, et al. Durability of mitral valve repair for degenerative disease. J Thorac Cardiovasc Surg. 1998;116:734–43.PubMedCrossRefGoogle Scholar
  41. 41.
    Hauck AJ, Freeman DP, Ackermann DM, et al. Surgical pathology of the tricuspid valve: a study of 363 cases spanning 25 years. Mayo Clin Proc. 1988;63:851–63.PubMedCrossRefGoogle Scholar
  42. 42.
    Moller JE, Connolly HM, Rubin J, et al. Factors associated with progression of carcinoid heart disease. N Engl J Med. 2003;348:1005–15.PubMedCrossRefGoogle Scholar
  43. 43.
    Simula DV, Edwards WD, Tazelaar HD, et al. Surgical pathology of carcinoid heart disease: a study of 139 valves from 75 patients spanning 20 years. Mayo Clin Proc. 2002;77:139–47.PubMedGoogle Scholar
  44. 44.
    Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr. 2009;22:1–23.PubMedCrossRefGoogle Scholar
  45. 45.
    Al Zaibag M, Ribeiro P, Al Kasab S. Percutaneous balloon valvotomy in tricuspid stenosis. Br Heart J. 1987;57:51–3.PubMedCrossRefGoogle Scholar
  46. 46.
    Singh JP, Evans JC, Levy D, et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol. 1999;83:897–902.PubMedCrossRefGoogle Scholar
  47. 47.
    Taramasso M, Vanermen H, Maisano F, et al. The growing clinical importance of secondary tricuspid regurgitation. J Am Coll Cardiol. 2012;59:703–10.PubMedCrossRefGoogle Scholar
  48. 48.
    Topilsky Y, Tribouilloy C, Michelena HI, et al. Pathophysiology of tricuspid regurgitation: quantitative Doppler echocardiographic assessment of respiratory dependence. Circulation. 2010;122:1505–13.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  • Sammy Elmariah
    • 1
  • James L. JanuzziJr.
    • 2
  • James L. JanuzziJr.
    • 3
  • Aidan W. Flynn
    • 4
  • Praveen Mehrotra
    • 4
  • Igor F. Palacios
    • 5
  • Igor F. Palacios
    • 6
    • 7
  1. 1.Harvard Medical School Interventional Cardiology, Cardiology Division, Department of MedicineMassachusetts General HospitalBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA
  3. 3.Cardiac Intensive Care Unit, Cardiology Division, Department of MedicineMassachusetts General HospitalBostonUSA
  4. 4.Harvard Medical School Cardiology Division, Department of MedicineMassachusetts General HospitalBostonUSA
  5. 5.Harvard Medical SchoolBostonUSA
  6. 6.Knight Catheterization LaboratoryBostonUSA
  7. 7.Interventional Cardiology, Cardiology Division, Department of MedicineMassachusetts General HospitalBostonUSA

Personalised recommendations